Tan Ho

Array ( [id] => 20499940 [patent_doc_number] => 20260029399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-29 [patent_title] => LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY [patent_app_type] => utility [patent_app_number] => 19/350928 [patent_app_country] => US [patent_app_date] => 2025-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11345 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19350928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20499939 [patent_doc_number] => 20260029398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-29 [patent_title] => LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY [patent_app_type] => utility [patent_app_number] => 19/350804 [patent_app_country] => US [patent_app_date] => 2025-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19350804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20567127 [patent_doc_number] => 20260061045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-05 [patent_title] => METHOD FOR PREVENTION AND TREATMENT OF VIRAL DISEASE [patent_app_type] => utility [patent_app_number] => 19/320827 [patent_app_country] => US [patent_app_date] => 2025-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14639 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19320827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20511313 [patent_doc_number] => 20260035414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-05 [patent_title] => HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/287448 [patent_app_country] => US [patent_app_date] => 2025-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34810 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19287448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20288615 [patent_doc_number] => 20250313858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-09 [patent_title] => SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES [patent_app_type] => utility [patent_app_number] => 19/183257 [patent_app_country] => US [patent_app_date] => 2025-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19183257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20316734 [patent_doc_number] => 12455280 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Ligand discovery and gene delivery via retroviral surface display [patent_app_type] => utility [patent_app_number] => 19/014949 [patent_app_country] => US [patent_app_date] => 2025-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 34 [patent_no_of_words] => 11286 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19014949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19860782 [patent_doc_number] => 20250099568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => Chimeric Flavivirus Lyssavirus Vaccines [patent_app_type] => utility [patent_app_number] => 18/777908 [patent_app_country] => US [patent_app_date] => 2024-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18777908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19785561 [patent_doc_number] => 20250059240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-20 [patent_title] => Antigenic Respiratory Syncytial Virus Polypeptides [patent_app_type] => utility [patent_app_number] => 18/775573 [patent_app_country] => US [patent_app_date] => 2024-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18775573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19693268 [patent_doc_number] => 20250011813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => Inducible AAV REP genes [patent_app_type] => utility [patent_app_number] => 18/774670 [patent_app_country] => US [patent_app_date] => 2024-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18774670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116018 [patent_doc_number] => 12365707 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Methods and products for genetic engineering [patent_app_type] => utility [patent_app_number] => 18/742986 [patent_app_country] => US [patent_app_date] => 2024-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 34 [patent_no_of_words] => 17107 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18742986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570412 [patent_doc_number] => 20240374704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR CORONAVIRUS PROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/637145 [patent_app_country] => US [patent_app_date] => 2024-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19512124 [patent_doc_number] => 20240343810 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY [patent_app_type] => utility [patent_app_number] => 18/616452 [patent_app_country] => US [patent_app_date] => 2024-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 104704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18616452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202836 [patent_doc_number] => 20240174735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/440344 [patent_app_country] => US [patent_app_date] => 2024-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19216339 [patent_doc_number] => 20240181043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => IDENTIFYING PATIENT POPULATIONS VULNERABLE TO VIRAL INFECTION AND METHODS OF INDUCING HETEROLOGOUS IMMUNITY IN SAME [patent_app_type] => utility [patent_app_number] => 18/440735 [patent_app_country] => US [patent_app_date] => 2024-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20158207 [patent_doc_number] => 12384819 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Modified cytomegalovirus proteins and stabilized complexes [patent_app_type] => utility [patent_app_number] => 18/435026 [patent_app_country] => US [patent_app_date] => 2024-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 46021 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18435026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554966 [patent_doc_number] => 20240366758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS [patent_app_type] => utility [patent_app_number] => 18/420532 [patent_app_country] => US [patent_app_date] => 2024-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20700269 [patent_doc_number] => 12622960 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-12 [patent_title] => Varicella zoster virus (VZV) vaccine [patent_app_type] => utility [patent_app_number] => 18/416835 [patent_app_country] => US [patent_app_date] => 2024-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 41 [patent_no_of_words] => 73838 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 260 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18416835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297708 [patent_doc_number] => 20240226274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => RECOMBINANT VIRAL CLASS I FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/404463 [patent_app_country] => US [patent_app_date] => 2024-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18404463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127626 [patent_doc_number] => 20240132979 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => Primers and Probes and Reagent Kit for Synchronous Detection of CymMV, ORSV, and CymRSV, and Applications Thereof [patent_app_type] => utility [patent_app_number] => 18/401631 [patent_app_country] => US [patent_app_date] => 2024-01-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18401631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343649 [patent_doc_number] => 20240252612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => IMMUNOGENIC COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/533167 [patent_app_country] => US [patent_app_date] => 2023-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 104158 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18533167 [rel_patent_id] =>[rel_patent_doc_number] =>)